Form 4: Arcus Biosciences CEO Transfers Shares to Family Trusts

Arcus Biosciences CEO Terry J. Rosen transferred 2,400 shares of common stock to family trusts, retaining voting and dispositive power.

Summary

• Terry J. Rosen, Chief Executive Officer and Director of Arcus Biosciences, Inc., reported a change in beneficial ownership.
• On December 30, 2025, 2,400 shares of Arcus Biosciences common stock were disposed of via a gift (Transaction Code G).
• The shares were transferred to various family trusts.
• Rosen retains voting and dispositive power over all of the shares transferred to each trust, despite having no pecuniary interest in them.
• Following this transaction, Rosen beneficially owns 2,192,409 shares of Arcus Biosciences common stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider disclosure of a gift transaction for estate planning purposes, with the insider retaining voting control. It does not inherently signal positive or negative sentiment about the company's operational performance or future prospects.

Positives

• The CEO retains voting and dispositive power over the transferred shares, indicating continued influence over the company's direction.

Negatives

• The CEO no longer holds a direct pecuniary interest in the 2,400 transferred shares, which represents a slight reduction in direct financial alignment, though voting power is maintained.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction disclosure and does not provide specific industry context. Such transfers to family trusts are common for high-net-worth individuals for estate planning purposes.

Related Party Transactions

• Terry J. Rosen, CEO and Director, transferred 2,400 shares of Arcus Biosciences common stock to various family trusts, where he retains voting and dispositive power.

Stakeholder Impact

• Shareholders: Minimal direct impact as the CEO retains voting control over the shares, indicating continued alignment of influence, though direct pecuniary interest in these specific shares is removed.
• Management: The CEO's personal estate planning decision, with no direct operational impact on the company.

Key Dates

Recommendation

This Form 4 filing details a routine insider gift transaction by the CEO to family trusts for estate planning purposes. While the CEO no longer has a direct pecuniary interest in the 2,400 shares transferred, he retains full voting and dispositive power, maintaining his influence over these shares. This type of transaction is generally not indicative of a change in the company's fundamentals or the CEO's confidence in the company's long-term prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing. A 'hold' recommendation is appropriate as this disclosure provides no new information to alter an existing investment thesis.

Keywords

Arcus Biosciences, RCUS, Form 4, Insider Transaction, Stock Transfer, CEO, Terry J. Rosen, Family Trust, Beneficial Ownership